升降散汤药对痰热壅肺型重症肺炎患者的临床疗效及血清炎症因子的影响

目的研究升降散汤药对痰热壅肺型重症肺炎患者的临床疗效及血清炎症因子的影响。方法选取2017年7月至2018年9月在上海市光华中西医结合医院住院的重症肺炎患者74例作为研究对象,采用随机数字表法分为对照组(34例)和治疗组(40例)。对照组患者给予常规药物治疗,治疗组患者在常规治疗的基础上加用升降散汤药。采用ELISA检测C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素(IL)-1β、IL-2R、肿瘤坏死因子-α(TNF-α)、IL-6、IL-8、IL-10水平并采用t检验进行两组比较。评价两组患者治疗前后中医证候积分。结果治疗组患者治疗后CRP、PCT、IL-1β、IL-2R、TNF-α、IL-6水平及中医证候积分均低于对照组,IL-10水平高于对照组,差异均有统计学意义(P<0.05);治疗组患者总有效率高于对照组,差异有统计学意义(P<0.05);两组患者均无明显不良事件发生。结论升降散汤药能降低痰热壅肺型重症肺炎患者的血清炎症因子水平,提高临床有效性,适宜在重症肺炎中使用。

The effect of Shengjiang Powder Decoction on the clinical efficacy and serum inflammatory factors in the patients with lung type severe pneumonia of phlegm heat stagnation type

Objective To study the effect of Shengjiang Powder Decoction on the clinical effect and serum inflammatory factors in patients with lung type severe pneumonia of phyegm heat stagnation type.Methods A total of 74 patients with severe pneumonia hospitalized in Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine from July 2017 to September 2018 were randomly divided into control group(34 cases)and treatment group(40 cases).The control group was treated with conventional medicine,and the treatment group was treated with Shengjiang Powder Decoction on the basis of conventional treatment.ELISA method was used to detect C-reactive protein(CRP),procalcitonin(PCT),interleukin(IL)-1β,IL-2R,tumor necrosis factor(TNF)-α,IL-6,IL-8,IL-10,and then t-test was used to analyze the levels between the two groups.The TCM symptom scores of the two groups before and after treatment were evaluated.Results CRP,PCT,IL-1β,IL-2R,TNF-α,IL-6 and the TCM symptom scores in the treatment group were lower than those in the control group,IL-10 was higher than that in the control group,and the differences were statistically significant(P<0.05).The overall effective rate in the treatment group was higher than that in the control group,and there was no significant adverse event in the two groups.Conclusion Shengjiang Powder Decoction can reduce the inflammatory reaction and improve the clinical efficacy in the severe pneumonia patients with lung type of phlegm heat stagnation.